Briokem 50
Briokem 50 - Image 2
Briokem 50 - Image 3
, , ,

Briokem 50

Composition:

  • Brivaracetam 50 mg
    Therapeutic Class:

  • Antiepileptic / Anticonvulsant
    Schedule: Schedule H1 (Prescription Only + Special Monitoring Required)

Briokem 50 contains Brivaracetam, a novel antiepileptic drug (AED) that acts as a high-affinity synaptic vesicle protein 2A (SV2A) ligand, designed for adjunctive treatment of focal seizures in adults and adolescents. It offers a faster onset of action, improved CNS tolerability, and fewer behavioral side effects compared to traditional AEDs.

Usage of Briokem 50

Briokem 50 is indicated for:

  • Focal onset seizures (partial seizures) with or without secondary generalization

  • Adjunct therapy in patients with epilepsy not fully controlled on current regimen

  • Can also be used in generalized epilepsy (off-label in some settings)

Mechanism of Action

Brivaracetam selectively binds to SV2A, a synaptic vesicle protein involved in neurotransmitter release modulation, resulting in:

  • Suppression of neuronal hyperexcitability

  • Inhibition of epileptic activity spread

  • Improved seizure control with minimal sedation

Compared to levetiracetam, Brivaracetam has 20x higher affinity for SV2A and lower risk of irritability, agitation, or mood changes.

Key Benefits

✅ Rapid onset of antiepileptic action
✅ Improved behavioral and psychiatric tolerability
✅ Lower incidence of drowsiness, dizziness, and fatigue
✅ Safe as add-on therapy with most AEDs
✅ No need for titration in most patients — easy to initiate

Common Side Effects

  • Somnolence or dizziness (dose-dependent)

  • Fatigue

  • Nausea or irritability (mild and self-limiting)

  • Rare: Mood swings, aggression, suicidal thoughts (monitor closely)

Precautions

  • Use cautiously in patients with depression or psychiatric history

  • May cause drowsiness or impaired driving ability

  • Monitor behavior, especially during initial weeks of therapy

  • Avoid abrupt discontinuation to prevent withdrawal seizures

  • Dose adjustment may be required in severe hepatic impairment

Drug Interactions

  • Minimal drug interactions due to limited CYP metabolism

  • Can be safely co-administered with most AEDs (lamotrigine, valproate, carbamazepine, etc.)

  • Avoid use with alcohol or CNS depressants

  • May slightly interact with rifampicin, carbamazepine epoxide (reduce efficacy)

Dosage and Administration

  • Usual dose: 50 mg twice daily (can be increased to 100 mg BID if needed)

  • Can be taken with or without food

  • No need for slow titration in most cases

  • Do not crush or split the tablet

Storage

  • Store at room temperature below 25°C

  • Protect from moisture and direct sunlight

  • Keep out of reach of children

Patient Counseling Points

  • Take the medication at the same time each day

  • Do not stop abruptly — consult physician if side effects occur

  • Inform your doctor about any mood changes, irritability, or suicidal thoughts

  • Avoid driving or operating machinery until the effect is known

  • Regular follow-ups for seizure control and side effect monitoring are important

Related products